<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-153089</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Identification and in vitro antifungal susceptibility of vaginal Candida spp. isolates to fluconazole, clotrimazole and nystatin</dc:title>
<dc:description xml:lang="en">Objective. The aim of this study was to identify and determine the in vitro antifungal susceptibility testing to clotrimazole, fluconazole, and nystatin of 145 clinical isolates of Candida spp. Material and methods. M27-A3 microdilution method was used to determine minimal inhibitory concentrations (MIC) and partial MICs (MIC50 and MIC90) of drugs. A total of 145 isolates were studied, 126 were C. albicans, 16 C. glabrata, 2 C. parapsilosis y 1 C. tropicalis. Results. MIC50 and MIC90 for FLZ against C. albicans were 0.25 mg/L and 1 mg/L respectively and for C. glabrata was achieved at 8 mg/L and 16 mg/L for fluconazole. Five isolates of C. albicans and one isolate of C. tropicalis were in vitro resistant to fluconazole (M27-S4). In C. albicans MIC50 and MIC90 for clotrimazole were of 0.03 mg/L and 0.06 mg/L, respectively. These values for C. glabrata were 0.25 mg/L and 1 mg/L, respectively. Five C. glabrata and 1 C. tropicalis were in vitro resistant to clotrimazole. MIC50 and MIC90 of nystatin were of 1 mg/L and 2 mg/L, respectively for C. albicans and C. glabrata. Conclusion. In this study, C. albicans is the most frequently isolated yeast, followed by C glabrata. The antifungals tested were found to be in vitro active for the isolates, except for 6 isolates for fluconazole and 6 to clotrimazole (AU)</dc:description>
<dc:creator>Diaz, María Cristina</dc:creator>
<dc:creator>Camponovo, Rossanna</dc:creator>
<dc:creator>Carrillo-Muñoz, Alfonso-Javier</dc:creator>
<dc:creator>Santander, María Paola</dc:creator>
<dc:creator>Araya, Ingrid</dc:creator>
<dc:creator>Cerda, Ann</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Identificar especie y determinar la sensibilidad in vitro a clotrimazol, fluconazol y nistatina de 145 aislamientos de Candida spp. Material y métodos. Se utilizó un método de microdilución en caldo (M27-A3) para determinar la concentración inhibitoria mínima (CMI) y además las CMI50 y CMI90 de los antifúngicos. De los 145 aislamientos, 126 correspondieron a C. albicans, 16 C. glabrata, 2 C. parapsilosis y 1 C. tropicalis. Resultados. La CMI50 y CMI90 de fluconazol frente C. albicans fueron de 0,25 mg/L y 1 mg/L y para C. glabrata de 8 y 16 mg/L, respectivamente. Cinco aislados de C. albicans y un aislado de C. tropicalis fueron resistentes a fluconazol (M27- S4). Las CIM50 y CIM90 de clotrimazol frente a C. albicans fueron 0,03 mg/L y 0,06 mg/L y para C. glabrata de 0,25 mg/L y 1 mg/L, mientras que para nistatina fueron de 1 mg/L y de 2 mg/L, respectivamente para C. albicans y C. glabrata. Cinco aislados de C. glabrata y 1 de C. tropicalis fueron resistentes a clotrimazol. Conclusión. En este estudio, C. albicans es la levadura más frecuentemente aislada, seguida de C glabrata. Los antifúngicos evaluados resultaron ser activos in vitro para las cepas aisladas, excepto en 6 aislados para fluconazol y 6 para clotrimazol (AU)</dc:description>
<dc:source>Rev Esp Quimioter;29(3): 151-154, jun. 2016. ab</dc:source>
<dc:identifier>ibc-153089</dc:identifier>
<dc:title xml:lang="es">Identificación y sensibilidad antifúngica in vitro de Candida spp. de origen vaginal a fluconazol, clotrimazol y nistatina</dc:title>
<dc:subject>^d24654^s22073</dc:subject>
<dc:subject>^d2213^s22016</dc:subject>
<dc:subject>^d19042^s22074</dc:subject>
<dc:subject>^d28213^s22073</dc:subject>
<dc:subject>^d29310</dc:subject>
<dc:subject>^d19042^s22045</dc:subject>
<dc:subject>^d2213^s22057</dc:subject>
<dc:subject>^d2213^s22046</dc:subject>
<dc:subject>^d3049^s22073</dc:subject>
<dc:subject>^d24244^s22045</dc:subject>
<dc:subject>^d2207^s22021</dc:subject>
<dc:subject>^d2208^s22021</dc:subject>
<dc:subject>^d2207^s22001</dc:subject>
<dc:subject>^d2208^s22001</dc:subject>
<dc:type>article</dc:type>
<dc:date>201606</dc:date>
</metadata>
</record>
</ibecs-document>
